1	mRNA COVID-19 vaccine booster fosters B and T cell responses in immunocompromised
2	patients.
3	Elena Azzolini ^{1,2,*} , Chiara Pozzi ^{2,*} , Luca Germagnoli ² , Bianca Oresta ³ , Nicola Carriglio ³ , Mariella Calleri ³ ,
4	Carlo Selmi ^{1,2} , Maria De Santis ^{1,2} , Silvia Finazzi ² , Carmelo Carlo-Stella ^{1,2} , Alexia Bertuzzi ² , Francesca
5	Motta ^{1,2} , Angela Ceribelli ^{1,2} , Alberto Mantovani ^{1,2,4} , Fabrizio Bonelli ³ and Maria Rescigno ^{1,2,#}
6	
7	¹ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20072 Pieve
8	Emanuele, MI, Italy.
9	² IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, MI, Italy.
10	³ DiaSorin S.p.A., Via Crescentino, I-13040 Saluggia, VC, Italy.
11	⁴ The William Harvey Research Institute, Queen Mary University of London, London, UK
12	
13	*These authors contributed equally to the work
14	
15	
16	[#] Corresponding author
17	E-mail: maria.rescigno@hunimed.eu
18	Humanitas University
19	Via Rita Levi Montalcini, 4
20	20072 Pieve Emanuele (MI) Italy
21	

23 Abstract

24 SARS-CoV-2 vaccination has proven effective in inducing an immune response in healthy individuals and is 25 progressively allowing to overcome the pandemic. Recent evidence has shown that response to vaccination 26 in some vulnerable patients may be diminished, and it has been proposed a booster dose. We tested the 27 kinetic of development of serum antibodies to the SARS-CoV-2 Spike protein, their neutralizing capacity, 28 the CD4 and CD8 IFN-y T cell response in 328 subjects, including 131 immunocompromised individuals 29 (cancer, rheumatologic, and hemodialysis patients), 160 healthcare workers (HCW) and 37 subjects older 30 than 75 yo, after vaccination with two or three doses of mRNA vaccines. We stratified the patients according 31 to the type of treatment. We found that immunocompromised patients, depending on the type of treatment, 32 poorly respond to SARS-CoV-2 mRNA vaccines. However, an additional booster dose of vaccine induced a 33 good immune response in almost all of the patients except those receiving anti-CD20 antibody. Similarly to 34 HCW, previously infected and vaccinated immunocompromised individuals demonstrate a stronger SARS-35 CoV-2 specific immune response than those who are vaccinated without prior infection. 36 37 **Running title** 38 COVID-19 vaccine booster in immunocompromised patients. 39 40 Summary blurb (200 characters) 41 Immunocompromised patients poorly respond to two doses of SARS-CoV-2 mRNA vaccines. However, an 42 additional booster dose elicits a strong humoral and cellular immune response in these subjects.

43

45 Introduction

46 From December 2020 several anti-SARS-CoV-2 vaccines have been approved by the drug authority 47 agencies for emergency use for the prevention and management of COVID-19. SARS-CoV-2 vaccination 48 has proven to be effective in protecting against hospitalization and death in Israel (Haas et al, 2021), and, 49 as shown by the COVID-19 vaccine breakthrough infection surveillance, also in the US even towards the 50 Delta variant (Scobie et al, 2021). This indicates that vaccines can help control COVID-19 severity and 51 the pandemic itself. Indeed, all of the vaccines approved so far have proven great efficacy in activating an 52 immune response in healthy individuals (Abu Jabal et al, 2021; Arunachalam et al, 2021a; Arunachalam et 53 al, 2021b; Dagan et al, 2021; Haas et al, 2021; Polack et al, 2020; Voysey et al, 2021; Walsh et al, 2020) 54 and we and others have shown that one dose is sufficient in boosting the immune response in SARS-CoV-55 2 previously exposed subjects (Krammer et al, 2021a; Krammer et al, 2021b; Levi et al, 2021; Saadat et 56 al, 2021; Sadoff et al, 2021; Samanovic et al, 2021). However, the ability of mRNA-based SARS-CoV-2 57 vaccines to immunize primary or treatment-induced immunocompromised individuals has recently been 58 questioned (Collier et al, 2021). In particular, patients with inflammatory bowel disease under infliximab 59 treatment (Kennedy et al, 2021), patients who have received an allogeneic stem cell transplantation 60 (Lafarge et al, 2022), cancer patients (Chung et al, 2021; Greenberger et al, 2021a; Greenberger et al, 61 2021b; Ribas et al, 2021; Thakkar et al, 2021a; Thakkar et al, 2021b; Zeng et al, 2021), methotrexate 62 treatment (Mahil et al, 2021), kidney transplant or hemodialysis (Danthu et al, 2021) (Bachelet et al, 2021) 63 or multiple sclerosis (Apostolidis et al, 2021) have all demonstrated a reduced ability to mount an 64 immune response, potentially adversely affecting protection offered by vaccines. However, studies in 65 which a comprehensive comparative analysis of both humoral and cellular immune responses after a third 66 dose of vaccine is lacking.

Indeed, the type of immunomodulatory treatment may have a differential effect according to the immune cell which is targeted. For instance, B-cell-directed therapies for hematological malignancies have been shown to affect the production of antibodies in response to SARS-CoV-2 vaccination due to B-cell depletion and/or disruption of the B-cell receptor signaling pathway while leaving unaltered the T cell response (Apostolidis et al, 2021). This T cell response may compensate for the B cell response and may explain why anti-CD20 treated patients are still protected from COVID-19 (Huang et al, 2021). By 73 contrast, a general immune suppression due to drug treatments or the disease itself may affect both 74 humoral and cellular responses. Hence, it is very important to evaluate the immunization status and the 75 duration of response in immunocompromised patients undergoing SARS-CoV-2 vaccination and relate it 76 to the type of treatment. Here, we compared the antibody production, CD4 and CD8 T cell response to the 77 vaccine spike protein, as well as the neutralization potential of the antibody response in response to 2 or 3 78 doses of SARS-CoV-2 vaccine in 328 subjects including healthcare workers (HCW), elderly subjects (>75 79 vo) and immunocompromised patients with different pathologies either in hemodialysis, with cancer or 80 rheumatological diseases in relation to their treatments.

81 We show that one of the major determinants of a successful immune response was the immune status, 82 exposure to SARS-CoV-2 infection and type of treatment at the time of vaccination and that three doses of 83 vaccine allowed achieve immunization even in immunocompromised individuals. However, as expected, 84 anti-CD20 treatment impaired the development of an antibody response even after the third dose, 85 suggesting that patients under this treatment should wait to receive the shots after interrupting the therapy. 86 Patients under mycophenolate also respond poorly to vaccination, but interruption of therapy for just one 87 week allows activation of the immune response. We also show that SARS-CoV-2 recovered 88 immunocompromised individuals, similarly to healthy subjects (Krammer et al, 2021a; Krammer et al, 89 2021b; Levi et al, 2021; Saadat et al, 2021; Sadoff et al, 2021; Samanovic et al, 2021), achieved a strong 90 immune response, quicker than naïve subjects. Overall, this study highlights a need in a booster dose of 91 vaccine in immunocompromised individuals, which should however consider their immune status and 92 treatment. SARS-CoV-2 recovered patients instead, should be considered for the booster dose on an 93 individual basis.

94

95 Results

96 Clinical study

97 In this observational study we analyzed the antibody production, the CD4 and CD8 T cell and the 98 neutralizing antibody response to SARS-CoV-2 Spike protein in 328 subjects (Table 1) including 99 healthcare workers (n= 160), elderly people >65 yo (n=37), and 131 immunocompromised patients with 100 different pathologies including patients in hemodialysis (n=53), with cancer (n=30) or rheumatological 101 disease (n=48) at 2-4 months (T3) after the second dose of mRNA SARS-CoV-2 vaccination (Spikevax or 102 Comirnaty). For immunocompromised patients we investigated the humoral and cellular immune response 103 also at 2 weeks after the third (booster) dose (T4). In particular, 13 (44%) cancer patients, 31 (65%) 104 patients with rheumatic disease and 44 (83%) patients in hemodialysis received the third dose. Moreover, 105 for HCW and cancer patients we tested the kinetics of B and T cell development before vaccination (T0) 106 at 21-28 days after the first dose (T1), 10-26 days after dose 2 (T2) and 2-4 months (T3) after the second 107 dose (Fig. 1). 62 individuals had been previously exposed to SARS-CoV-2 (Table 1) and among these, 108 only 6 out of 18 (33%) cancer patients, 1 out of 5 (20%) hemodialysis patients and 1 (100%) rheumatic 109 disease patient received the third dose. The immune response was correlated with the type of pathology, 110 the immune status and the treatment (Table 2).

111

112 SARS-CoV-2 naïve cancer patients treated with anti-CD20 fail to produce neutralizing antibodies.

113 SARS-CoV-2 particle internalization is mediated by the binding of the trimeric form of the Spike protein 114 with the ACE-2 receptor on host cells (Hoffmann et al, 2020). We chose to test the level of IgG antibodies 115 directed to the trimeric form of Spike protein (LIAISON[®] SARS-CoV-2 TrimericS IgG, DiaSorin) to have 116 a better correlation with neutralizing antibodies. Nevertheless, we also tested the neutralization ability of 117 the ensued antibodies via a surrogate test of Spike neutralization (cPassTM, GenScript). As shown in Suppl. 118 figure 1A, while the antibody response was induced in healthcare workers already after the first vaccine 119 dose (T1) and reached a climax 10 days after the second dose (T2), it was either undetectable in cancer 120 patients receiving anti-CD20 treatment (blue triangles, category 2) or reduced in patients receiving other 121 drugs with low/medium impact to the immune system (orange and green/yellow triangles, categories 0 or 122 1, respectively) at any time point between T0 and T3 (Fig. S1 A). In those patients that experienced an 123 antibody response, the titers were much lower than those of the HCW suggesting that the amplitude of the 124 antibody response was compromised. However, a booster dose of vaccine increased the antibody titers at 125 levels similar to those of HCW, except for anti-CD20 treated cancer patients which remained undetectable 126 (Fig. S1 A, T4). As the latter patients were discouraged to take a booster dose, we could test only three out 127 of eight patients who insisted to receive it. Wherever detectable, the antibodies were neutralizing and were 128 preserved at least four months after vaccination (T3), but only in those patients that were not in active 129 treatment at the time of vaccination (orange triangles, Fig. S1 A and Table 2). By contrast, the antibodies 130 raised in HCW were all neutralizing (Fig. S1 A). Regarding SARS-CoV-2 previously exposed individuals, 131 while nearly all HCW required one single dose to reach a very strong neutralizing antibody response, as 132 we and other previously described (Krammer et al, 2021a; Krammer et al, 2021b; Levi et al, 2021; Saadat 133 et al, 2021; Sadoff et al, 2021; Samanovic et al, 2021), SARS-CoV-2 naturally infected cancer patients 134 required two doses to reach comparable neutralizing antibodies (Fig. S1 B), but almost all of them (16 out 135 of 18) developed IgG antibody response, even if cancer patients were under active treatment at the time of 136 vaccination (12 out of 18, Fig. S1 B and Table 2). In particular, ten were treated with drugs belonging to 137 category 0, one with drug of category 1 (green triangles, Doxorubicin+Cisplatin) and one with anti-CD20 138 (blue triangles, category 2) (Fig. S1 B and Table 2). A booster dose increased the amount of serum 139 antibodies, particularly the neutralizing antibodies (Fig. S1 B, T4). The only naturally infected cancer 140 patient under active anti-CD20 treatment did not increase antibodies even after the second dose (T2) (blue 141 triangles, Fig. S1 B), and was advised to take a third dose after stopping the anti-CD20 treatment. A 142 higher number of patients under this treatment is required to reach any conclusions.

143

144 SARS-CoV-2 naïve cancer patients treated with anti-CD20 may fail to activate T cell responses.

145 The induction of a CD4 or CD8 T cell response is an additional arm of an effective vaccination. We thus 146 evaluated the kinetic of anti-Spike T cell response activation in the two groups, by using specific CD4 147 (Ag1) and CD4 plus CD8 (Ag2) T cell epitopes of the Spike protein. As shown in Suppl. figures 2A, we 148 found that the T cell response (both to Ag1 and Ag2) was low in general in cancer patients and was 149 observed only in three out of seven patients under anti-CD20 treatment at T2. Interestingly, the peripheral 150 blood T cell response dropped three months after vaccination in a good proportion of subjects, including 151 HCW, and in 9 out of 23 (Ag1) and in 5 out of 23 (Ag2) was below the threshold of positivity selected for 152 this study. The booster dose to cancer patients re-elevated the T cell response to levels similar to those 153 after the second dose but we did not observe further enhancement like that of the antibody response. Anti-154 CD20 treated patients that did not show a T cell response after the second dose, did not benefit from the 155 booster dose (Fig. S2 A). As shown in Fig. S2 B, the T cell response was boosted in all of naturally 156 infected subjects at T2, regardless of being HCW or cancer patients with or without treatment (even anti-

157 CD20) and it was high at 3-4 months after vaccination (T3) or at two weeks after the booster dose (T4).

158

159 The immune response is compromised in a substantial proportion of patients in hemodialysis and in 160 some rheumatologic patients but can be boosted by a third vaccine dose.

161 Prompted by the intriguing results on cancer patients and the dependence of the immune response on the 162 pharmacologic treatment, we evaluated whether other categories of immunocompromised patients 163 displayed a compromised immune response to the vaccine and the outcome after a booster dose. Thus, we 164 tested the trimeric antibody levels, their neutralization ability and T cell responses at 2-3 months from the 165 second dose (T3) and at two weeks after the booster dose (T4) in patients with rheumatic diseases or in 166 patients in hemodialysis. As patients in hemodialysis were older, we also included a group of elderly 167 people (≥75 yo) receiving the vaccine. As shown in Fig. 2 A, patients in hemodialysis had a significant 168 reduction in trimeric antibody response at 3 months after the second dose of vaccine (T3) compared to 169 health care workers (P < 0.0001) and a drastic but not significative reduction versus older subjects. This 170 response reflected also a significant reduction (P < 0.0001) in the neutralizing ability of the antibodies (Fig. 171 2 B) also in older subjects (P=0.0026). Rheumatic disease patients instead, as a group, had a reduction in 172 IgG trimeric antibody response, which was not statistically significant, however, the neutralization 173 potential was significantly reduced (P=0.0499) as compared to that of HCW individuals (Fig. 2, A and B). 174 Notably, 4 patients had no neutralizing antibodies, although 2 of them had a positive antibody test. As 175 shown in figure 2C and 2D, the T cell response (both Ag1 and Ag2) was significantly lower as compared 176 to HCW in hemodialysis patients (Ag1, P=0.0003; Ag2, P=0.0017), but not in the other patients. When 177 we analyzed the response at two weeks after the third dose (T4) we observed that all rheumatic patients 178 and dialysis patients (except for one patient of each class) had increased the serum levels of antibodies 179 (P < 0.0001) which were also neutralizing except for three patients in hemodialysis, two of them having 180 detectable trimeric antibodies (54.2 and 134 BAU/ml) which were not neutralizing (Fig. 2, A and B). 181 However, although the T cell response was boosted, with a statistically significant increase only in dialysis 182 patients (Ag1, P=0.0014; Ag2, P=0.0015), it remained below the limit of positivity set in this study for 183 many patients (Fig. 2, C and D). Importantly, in Fig. S3A we reported INF- γ basal levels, that may be produced by other cell types (e.g. NK cells), and that we found to be below the cut-off threshold for the majority of samples. As observed also for cancer patients, previously exposed to SARS-CoV-2 patients displayed the highest levels of neutralizing antibodies which remained high also after the booster dose (Fig. S4, A and B). Moreover, the T cell responses remained higher in SARS-CoV-2 experienced patients than naïve HCW (Fig. S4, C and D; Fig. S3 A).

189

190 The immune response depends on the type of treatment or immune status of the patients.

191 Having observed a clear reduction in antibody levels in cancer or hemodialysis patients and in some 192 rheumatologic disease patients, we analyzed whether the observed differences were linked to an immune 193 depressed state induced by the treatment or by their disease. As described in the methods section, we 194 classified the patients according to the type of treatment (cancer and rheumatic disease patients) or an 195 immunoscore related to the disease for which the patients are in dialysis and their comorbidities. As 196 shown in Fig. 3 A, S5A-B and S6A-B the type of treatment (no treatment or low (0), medium (1) or high 197 (2) interference with the immune system) or the worsening of the immunoscore in hemodialysis patients 198 (low (0), medium (1) or high (2) immune compromised) impacted on the profile of the immune response 199 with a progressive reduction of both antibody levels (Fig. 3 A, S5A-B and S6A-B) and neutralization 200 potential (Fig. 3 A). Interestingly, patients distributed quite homogenously in the three categories 201 suggesting that their immune status, rather than the disease itself, was responsible for the impaired 202 immune response. Particularly affected were patients belonging to category 2: patients in hemodialysis 203 with an high immune compromised immunescore, rheumatic disease patients treated with mycophenolate 204 or methotrexate and cancer patients treated with anti-CD20 (Fig. 3A, blue crosses, yellow or pink circles 205 and blue triangles, respectively; Fig. S5A-B and Fig. S6A-B). It should be noted that patients under 206 methotrexate stopped treatment one week after getting vaccinated and indeed they all developed 207 neutralizing antibodies (Fig. 3, A and B, pink circles). Interestingly, the third dose (T4) allowed patients in 208 category 2 to achieve levels of antibodies similar to those in category 1 at 2 / 4 months after the second 209 dose (T3) except for patients treated with anti-CD20 antibody (Fig. 3 A, blue triangles), one patient in 210 hemodialysis (Fig. 3 A, blue cross) and one patient with mycophenolate (Fig. 3 A, yellow circle). 211 Interestingly, the latter patient was advised to stop treatment for one week after vaccination, but did not 212 follow the advice. Patients in hemodialysis that were previously exposed to SARS-CoV-2 showed higher 213 levels of IgG compared to those that were not infected, even after 6 months from the second dose, at the 214 time of booster (Fig. S6, C and D). The booster dose increased significantly the neutralization ability of 215 IgG in all the categories (Fig. 3 B). The T cell response also was affected particularly by the category of 216 drugs with high interference with the immune system or by an immune compromised status (category 2), 217 but differences with patients belonging to category 0 or 1 were not striking at T3. Interestingly, T cell 218 response (both to Ag1 and Ag2) was statistically significantly boosted with a third dose only in category 2 219 patients (Fig. 3, C and D). Moreover, in Fig. S3 B we reported INF- γ basal levels, that we found to be 220 below the cut-off threshold for the majority of samples. Interestingly, when analyzing the correlation 221 between antibody levels and neutralization potential, we found that in the group of patients in the category 222 2 (treated with drugs with high interference with the immune system or immune compromised patients) 223 levels of trimeric antibody above 100 BAU/ml after the second dose are most likely to correspond to a 224 positive neutralization test (>30%) (Fig. 4 A). The booster dose allowed most of the patients achieve a 225 neutralizing antibody response, and it was confirmed that a level of antibodies above 100 BAU/ml 226 correlated with a positive neutralization test (Fig. 4 B).

227

228 Discussion

229 Here we show that, upon vaccination, elderly subjects and patients under treatments that have little or no 230 interference with the immune system develop an immune response which is slightly reduced but 231 comparable to that of healthy individuals, while those immunosuppressed (with an immunoscore equal to 232 2) or under immunosuppressive treatments are strongly impaired in the ability to activate an antibody 233 response (i.e., cancer patients treated with anti-CD20 therapy or rheumatic disease patients under active 234 treatment of mycophenolate). In some cases, the immune response is not initiated at all. However, a third 235 booster dose allows to achieve levels of neutralizing antibodies similar to those of HCW after the second 236 vaccine dose (T2) except for anti-CD20 treated cancer patients. By stratifying patients according to 237 treatment, we show that anti-CD20 and mycophenolate are the drugs with the highest impact on the 238 development of a correct immune response. By contrast, methotrexate which is associated with specific 239 immune inhibitory drugs did not have a major impact on the immune response, but it has to be considered 240 that methotrexate therapy was stopped for one week after every dose of vaccine, whereas mycophenolate 241 was not interrupted at the time of the first and second dose vaccination. This suggests that, wherever 242 possible, treatment having an impact on the immune system should be interrupted or delayed in order to 243 favor the development of an immune response. Indeed, at the administration of the third dose, 244 mycophenolate was interrupted and this resulted in a proficient activation of the immune response. The 245 patient who did not follow the advise of interrupting mycophenolate resulted in an undetectable antibody 246 and T cell response even after the third booster dose, confirming that treatment should be stopped to favor 247 the development of an immune response. Interestingly, as expected the antibody response to the trimeric 248 form of Spike was undetectable in individuals under anti-CD20 treatment, and the situation did not change 249 after the third dose. Interestingly also a patient that had interrupted anti-CD20 five months earlier still did 250 not display antibodies to the Spike trimeric protein. This is in line with a recent report showing that 251 patients with B-cell lymphoma (BCL) receiving B-cell-directed therapies should be vaccinated at least 252 nine months from the last treatment to improve antibody titers (Ghione et al, 2021). By contrast the T cell 253 response to AG1 and AG2 spike peptides was observed in three out of seven patients under anti-CD20 254 treatment at T2. This to us was unexpected as it has been shown that anti-CD20 treated multiple sclerosis 255 patients had a similar ability to induce T cells to the spike protein as healthy subjects (Apostolidis et al, 256 2021). This suggests that cancer patients may have an additional impairment in inducing the T cell 257 response which is probably unrelated to the active treatment. This makes cancer patients a very vulnerable 258 category that needs further attention. It would be important to correlate the vaccine immune response to 259 the stage of disease as the immune system may be depressed as a consequence of the immunosuppressive 260 status generated by the cancer itself. Indeed, it has been shown that COVID-19 mortality was statistically 261 significantly higher in cancer patients with an active disease (Pinato et al, 2020). Also, the immune status 262 of the patients is strongly correlated with the ensued immune response as indicated by the impact of 263 disease and immunoscore of patients in hemodialysis.

Regarding T cell analysis, we decided to test the T cell response by restimulating whole blood cells with specific peptides because we analyzed a population comprising immunocompromised individuals. Indeed, it is technically challenging to isolate T cells from immunocompromised individuals unless a large amount of blood is collected. It was already very difficult to recruit immunocompromised patients because of their 268 disease and treatments. In addition, many of them are continuously subjected to blood draws or treatments 269 that require intravenous access and it was unlikely that they may participate in a protocol asking to donate 270 more blood. This was a limitation along with the inability to measure the differences in T cell frequencies 271 among participants. Moreover, we cannot exclude that the IFN- γ measured after stimulation with SARS-272 COV-2 specific peptides could be produced also by other cell types (e.g. NK cells) and that the differences 273 observed between groups could be accounted for by differences in T cell skewing related to the disease 274 state and/or infection history. However, the finding that basal levels of IFN- γ were below the threshold 275 suggests that the observed production was due to peptide restimulation.

276 In conclusion, immunocompromised patients should be tested periodically to assess the development and 277 status of an immune response and should be considered individually and on the basis of their active 278 treatments with regards to a potential booster dose. Those that are not immunized should be prioritized to 279 receive a booster dose of vaccine and be re-evaluated afterwards for effective immunization. However, the 280 therapeutic schedule should be modulated (interrupted or delayed) to favor an immune response to the 281 vaccine. Particular attention should be given to patients with antibody levels below 100 BAU/ml because 282 these antibodies are unlikely to exert a neutralizing activity. A different scenario is observed in patients 283 previously exposed to SARS-CoV-2. These patients reach maximal response after two doses of vaccine, 284 still one subject under anti-CD20 treatment failed to activate an antibody response but developed a T cell 285 response. More SARS-CoV-2 exposed patients should be tested with immunosuppressive treatments to 286 draw conclusions.

287

288 Materials and methods

289 Study design

We tested the IgG antibody response, the CD4 and CD8 T cell activation and the neutralizing antibody response to SARS-CoV-2 spike protein developed after mRNA SARS-CoV-2 vaccination (Spikevax or Moderna mRNA-1273 – Comirnaty or BNT162b2 Pfizer-BioNTech) as a part of two observational studies approved by the Ethical Committee of Istituto Clinico Humanitas, in compliance with the Declaration of Helsinki principles. The studies were conducted at Istituto Clinico Humanitas and comprised a longitudinal sample collection, including healthcare workers (n=160) and cancer patients (n=30) and a cross-sectional sample collection, including elderly subjects (n=37), patients with rheumatic diseases (n=48) and patients in hemodialysis (n=53). Immunocompromised patients received also a third dose (booster) \pm 5 months after the second dose.

Analyzed time points were: the day of the first dose (T0), 21-28 days after the first dose (T1), 10-26 days after the second dose (T2), 2-4 months after the second dose (T3) and 2 weeks after the third dose (T4).

301 At each scheduled time point, as shown in Figure 1, serum and lithium-heparin whole blood samples were 302 collected from enrolled individuals. Study inclusion criteria included a vaccination with an authorized 303 COVID-19 vaccine (according to Italian regulation and guidelines), age of 18 years or greater, and 304 willingness and ability to provide informed consent. Study exclusion criteria included lack of willingness and 305 ability to provide informed consent, or a lack of properly collected and stored samples. Demographic and 306 clinical information for healthy subjects (healthcare workers and elderly) and patients can be found in Tables 307 1 and 2. Experiments were conducted in a blinded fashion with designated members of the clinical team, who did not run the assays, having access to the sample key until data were collected, at which point 308 309 researchers of the team were unblinded. All individuals enrolled in the studies provided an informed consent 310 as part of the protocols (CLI-PR-2102 and CLI-PR-2108;). These studies began in February 2021 (CLI-PR-311 2102) and June 2021 (CLI-PR-2108) and are continuing with participant's follow-up. Enrolled individuals 312 did not receive compensation for their participation.

313

314 **Patients and treatments**

315 Cancer and rheumatic disease patients were classified according to the type of treatment: no active treatment 316 or low (category 0), medium (category 1) or high (category 2) interference with the immune system (Table 317 2). In particular, drugs with low interference with the immune system (category 0) included: Tyrosine Kinase 318 Inhibitor, TKI (Imatinib), EGFR TKI (Osimertinib), chemotherapy (Lenalidomide, Docetaxel, Gemcitabine, 319 Nab-paclitaxel), hormone therapy, anti-HER2 agents (Pertuzumab, Trastuzumab), chemotherapy + anti-320 PDL1 (Carboplatin+etoposide+Atezolizumab) (for cancer patients) and ursodeoxycholic acid for rheumatic 321 diseases patients; drugs with medium interference with the immune system (category 1) were: Doxorubicin 322 (with Cisplatin or with Ifosfamide or present in ABVD) (for cancer patients) and anti-TNF Ab - Infliximab, 323 Certolizumab, Adalimumab, Golimumab; TNF blocker - Etanercept; JAK1/2 inhibitor - Baricitinib; 324 CD80/CD86 blocker – Abatacept (for rheumatic diseases patients); immunosuppressive drugs (category 2) 325 were rituximab, Obinutuzumab (for cancer patients), mycophenolate and methotrexate in combination with 326 immune inhibitory drugs (for rheumatic disease patients). Treatment with methotrexate or Baricitinib 327 (JAK1/2 inhibitor) was stopped one week after every dose of vaccine, whereas treatment with 328 mycophenolate was stopped one week only after the third dose of vaccine.

Patients in hemodialysis were classified with an immunoscore related to the disease for which the patients are in dialysis and their comorbidities: low (category 0), medium (category 1) or high (category 2) immune compromised (Table 2).

332

333 Detection of SARS-CoV-2 specific IgG antibodies

Serum samples were tested using LIAISON[®] SARS-CoV-2 TrimericS IgG (DiaSorin, Italy), a quantitative 334 335 CE-marked assay for the detection of IgG antibodies recognizing the native trimeric Spike glycoprotein of 336 SARS-CoV-2 (Bonelli et al, 2021). According to manufacturer's instruction for use, the presence of an 337 immune response in vaccine recipients was 100.0% (95% CI 96.3-100.0%) in 102 samples collected after 338 ≥ 21 days from second dose. The levels of IgG antibodies were originally expressed in arbitrary units 339 (AU/mL). Following the definition of the WHO International Standard for anti-SARS-CoV-2 340 Immunoglobulin (NIBSC 20:136), the readout was updated and the assay currently calculates the levels of 341 SARS-CoV-2 IgG antibodies in binding antibody units (BAU/mL) (Perkmann et al, 2021). Samples \geq 33.8 342 BAU/mL were considered positive. In Fig. S6, for the determination of IgG anti-SARS-CoV-2 in the serum 343 of patients in hemodialysis the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin) was used (Bonelli et al, 344 2020).

345 SARS-CoV-2 neutralization assay

Neutralization was assessed by ELISA with cPassTM SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, China), a qualitative CE-marked assay for the detection of circulating neutralizing antibodies that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor (Tan et al, 2020). Samples were analyzed following manufacturer's instruction for use. Samples \geq 30% signal inhibition were considered positive.

351 Detection of SARS-CoV-2 specific cell-mediated immunity

352 T cell-mediated responses were analyzed using QuantiFERON SARS-CoV-2 Research Use Only assay 353 (QIAGEN, Germany), following manufacturer's instruction for use. We tested the IFN-y production before 354 and after restimulation with SARS-CoV-2-specific antigens. Briefly, fresh whole blood samples were 355 collected in lithium-heparin tubes and maintained at room temperature for no more than 16 hours from the 356 time of collection. Each blood sample was transferred in a NIL-Tube (without antigens: this sample indicate 357 the IFN-y basal level, before restimulation) and in two QuantiFERON SARS-CoV-2 blood collection tubes 358 containing different cocktails of SARS-CoV-2-specific antigens (Ag1 and Ag2) and incubated at 37°C for 359 16-24 h. Plasma samples retrieved after centrifugation at 2,700 x g at room temperature for 15 min were 360 analyzed using LIAISON XL instrument (DiaSorin, Italy) for detection of IFN-y, according to the standard 361 procedures recommended by the manufacturer. For this study, positive results were defined as \geq 362 $0.25 \Box$ IU/mL, after IFN- γ basal level (NIL tube) was subtracted from Ag1 and Ag2 values. In Fig. S3 we 363 showed the IFN-γ basal level (IU/ml). We defined this tentative cut-off threshold based on previous 364 experience with the QuantiFERON test but this is arbitrary as other studies have defined a lower cut off 365 0.15 and 0.2 (Van Praet al, 2021). between et

366

367 Statistical analysis

368 Data were analyzed for normal distribution (Shapiro-Wilk test) before any statistical analyses. Individual 369 values are presented as spaghetti plots or as box plots showing the interquartile range, median, and 370 minimum-to-maximum whiskers. The differences between matched time points were analyzed using the 371 non-parametric Friedman test with Dunn's multiple comparisons test. The comparison of multiple groups 372 was carried out using the non-parametric Kruskal-Wallis test followed by Dunn's multiple comparisons test. 373 In order to gauge the correlation between IgG values in plasma (x variable) and the % of neutralization (y 374 variable), a non-parametric Spearman's rank correlation test was performed. A probability value of P < 0.05375 was considered significant. All statistics and reproducibility information are reported in the figure legends. 376 Data analyses were carried out using GraphPad Prism version 8.

377

378 Acknowledgments

379 The reagents in this study were supplied by DiaSorin (Italy) and QuantiFERON SARS-CoV-2 tubes by 380 QIAGEN (Germany). We acknowledge the full financial support of DiaSorin S.p.A. for CLI-PR-2102 and 381 CLI-PR-2108 clinical trials. In DiaSorin we would like to thank Elisa Ghezzi, Clara Rossini, and Chiara 382 Mauro for neutralization testing and Alice Bianchi for T cell response testing. We thank Jenny Howard, 383 Francis Stieber, and Vladyslav Nikolayevskyy from QIAGEN for their scientific support during the study. 384 We would like to thank all the employees and the patients that volunteered to participate to this study, all the 385 vaccinating doctors, the nurses and personnel that collected the samples, the laboratory technicians that run 386 the serological tests and Humanitas Operations Management and Customer Care that coordinated 387 vaccinations and blood draws.

388

389 Author contributions

390 All authors contributed to revise the manuscript for important intellectual content, were responsible for the 391 decision to submit for publication, and approved the final submitted version of the manuscript. E.A and C.P 392 contributed equally to the work. E.A. coordinated the recruitment and sampling of subjects (project 393 administration) and participated in clinical study design; C.P.: contributed to project administration, 394 performed data analysis and contributed to manuscript writing; L.G.: coordinated the laboratory analyses; 395 DiaSorin: carried out the laboratory analyses; B.O., N.C. and M.C. participated in clinical study design, 396 wrote the clinical protocols, contributed to project administration and to data analysis. C.S., M.DS., S.F., 397 C.C-S., A.B., F.M., A.C. recruited patients, reviewed and approved the manuscript. A.M.: conceptualization, 398 reviewed and approved the manuscript; F.B. designed the clinical study and coordinated the teams; M.R.: 399 conceived the study, analyzed the data and wrote the manuscript.

400

401 **Conflict of interests**

402 F.B., M.C., N.C., and B.O. are employees of DiaSorin S.p.A., the manufacturer of the LIAISON SARS-

403 CoV-2 TrimericS IgG test. Employees of DiaSorin participated in the study design, data collection and

404 interpretation and in the preparation of the manuscript. M.R. participated to advisory boards and received

405 support from Diasorin S.p.A. Other authors have declared that no conflict of interest exists.

407	Funding					
408	This work was supported by DiaSorin S.p.A. and Ricerca Corrente (Ministero della Salute, to M.R and					
409	A.M.).					
410						
411						
412	References					
413						
414	Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. (2021). Impact of age,					
415	ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2					
416	mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to					
417	January 2021. Euro Surveill 26:doi: 10.2807/1560-7917.ES.2021.26.6.2100096					
418	Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza					
419	DA, Kadri JC, et al. (2021). Cellular and humoral immune responses following SARS-CoV-2					
420	mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27:1990-2001.					
421	doi: 10.1038/s41591-021-01507-2					
422	Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, Grigoryan L, Trisal M, Edara VV, Lai					
423	L, et al. (2021a). Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature					
424	596 :410-416. doi: 10.1038/s41586-021-03791-x					
425	Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV,					
426	et al. (2021b). Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature					
427	594 :253-258. doi: 10.1038/s41586-021-03530-2					
428	Bachelet T, Bourdenx JP, Martinez C, Mucha S, Martin-Dupont P, Perier V, Pommereau A. (2021). Humoral					
429	response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2					
430	Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times. PLoS One					
431	16:e0257646. doi: 10.1371/journal.pone.0257646					
432	Bonelli F, Blocki FA, Bunnell T, Chu E, De La OA, Grenache DG, Marzucchi G, Montomoli E, Okoye L,					
433	Pallavicini L, et al. (2021). Evaluation of the automated LIAISON((R)) SARS-CoV-2 TrimericS IgG					
434	assay for the detection of circulating antibodies. Clin Chem Lab Med 59:1463-1467. doi:					
435	10.1515/cclm-2021-0023					
436	Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA, Pallavicini L, Chinali A,					
437	Campisi D, et al. (2020). Clinical and Analytical Performance of an Automated Serological Test					
438	That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively. J Clin Microbiol					
439	58 :doi: 10.1128/jcm.01224-20					
440	Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC,					
441	Boutemine SR, et al. (2021). Disease- and Therapy-Specific Impact on Humoral Immune Responses					

442 to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov 2:568-576. doi: 443 10.1158/2643-3230.Bcd-21-0139 444 Collier AY, Yu J, McMahan K, Liu J, Atyeo C, Ansel JL, Fricker ZP, Pavlakis M, Curry MP, Jacob-Dolan 445 C, et al. (2021). COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals. J 446 Infect Dis doi: 10.1093/infdis/jiab569 447 Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. 448 (2021). BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J 449 Med 384:1412-1423. doi: 10.1056/NEJMoa2101765 450 Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, El Ouafi Z, Ponsard S, Berrahal I, Achard JM, 451 et al. (2021). Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of 452 Hemodialysis Patients and Kidney Transplant Recipients. J Am Soc Nephrol 32:2153-2158. doi: 453 10.1681/ASN.2021040490 454 Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, et 455 al. (2021). Impaired humoral responses to COVID-19 vaccination in patients with lymphoma 456 receiving B-cell-directed therapies. Blood 138:811-814. doi: 10.1182/blood.2021012443 457 Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. (2021a). Anti-spike 458 antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic 459 malignancies. Cancer Cell 39:1297-1299. doi: 10.1016/j.ccell.2021.09.001 460 Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. (2021b). Antibody 461 response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39:1031-462 1033. doi: 10.1016/j.ccell.2021.07.012 463 Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et 464 al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections 465 and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in 466 Israel: an observational study using national surveillance data. Lancet 397:1819-1829. doi: 467 10.1016/S0140-6736(21)00947-8 468 Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu 469 NH, Nitsche A, et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 470 Blocked by a Clinically Proven Protease Inhibitor. Cell 181:271-280.e278. doi: 471 10.1016/j.cell.2020.02.052 472 Huang A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, Robinson J, Greenplate A, Porterfield F, 473 Owoyemi O, et al. (2021). CD8 T cells compensate for impaired humoral immunity in COVID-19 474 patients with hematologic cancer. Res Sq doi: 10.21203/rs.3.rs-162289/v1 475 Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, 476 Fraser A, et al. (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and 477 ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 70:1884-1893. doi: 478 10.1136/gutjnl-2021-324789

479	Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermudez-Gonzalez MC,
480	Bielak DA, Carreno JM, Chernet RL, et al. (2021a). Antibody Responses in Seropositive Persons
481	after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 384:1372-1374. doi:
482	10.1056/NEJMc2101667
483	Krammer F, Srivastava K, Simon V. (2021b). Robust spike antibody responses and increased reactogenicity
484	in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv
485	2021.2001.2029.21250653. doi: 10.1101/2021.01.29.21250653
486	Lafarge A, Mabrouki A, Yvin E, Bredin S, Binois Y, Clere-Jehl R, Azoulay E. (2022). Coronavirus disease
487	2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in
488	hematopoietic stem cell recipients. Curr Opin Crit Care 28:83-89. doi:
489	10.1097/mcc.00000000000000000000000000000000000
490	Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, Rescigno M. (2021). One dose of SARS-
491	CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from
492	symptomatic COVID-19. J Clin Invest 131: doi: 10.1172/JCI149154
493	Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry D, Brown MA, Cope AP, Dasandi T, Graham
494	C, Lechmere T, et al. (2021). The effect of methotrexate and targeted immunosuppression on
495	humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
496	Lancet Rheumatol 3:e627-e637. doi: 10.1016/S2665-9913(21)00212-5
497	Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, Wolzt M, Wagner OF,
498	Binder CJ, Haslacher H. (2021). Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody
499	Levels: a Head-to-Head Comparison of Five Quantitative Assays. Microbiol Spectr 9:e0024721. doi:
500	10.1128/Spectrum.00247-21
501	Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R,
502	Segui E, et al. (2020). Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
503	Cancer Discov 10:1465-1474. doi: 10.1158/2159-8290.Cd-20-0773
504	Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED,
505	Zerbini C, et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J
506	Med 383:2603-2615. doi: 10.1056/NEJMoa2034577
507	Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM. (2021). How to
508	Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood
509	Cancer Discov 2:562-567. doi: 10.1158/2643-3230.Bcd-21-0166
510	Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. (2021).
511	Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers
512	Previously Infected With SARS-CoV-2. JAMA 325:1467-1469. doi: 10.1001/jama.2021.3341
513	Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W,
514	Leroux-Roels I, et al. (2021). Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19
515	Vaccine. N Engl J Med 384:1824-1835. doi: 10.1056/NEJMoa2034201

516 Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, Hyman SW, Moritz 517 G, Ali M, Koralov SB, et al. (2021). Poor antigen-specific responses to the second BNT162b2 518 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv 2021.2002.2007.21251311. 519 doi: 10.1101/2021.02.07.21251311 520 Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, Bertolino D, Blythe D, Brady S, 521 Cadwell B, et al. (2021). Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, 522 by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep 523 70:1284-1290. doi: 10.15585/mmwr.mm7037e1 524 Tan CW, Chia WN, Oin X, Liu P, Chen MI, Tiu C, Hu Z, Chen VC, Young BE, Sia WR, et al. (2020). A 525 SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-526 spike protein-protein interaction. Nat Biotechnol 38:1073-1078. doi: 10.1038/s41587-020-0631-z 527 Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica 528 RA, et al. (2021a). Seroconversion rates following COVID-19 vaccination among patients with 529 cancer. Cancer Cell 39:1081-1090.e1082. doi: 10.1016/j.ccell.2021.06.002 530 Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, 531 et al. (2021b). Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease 532 and association with anticancer therapy. Nat Cancer 2:392-399. doi: 10.1038/s43018-021-00191-y 533 Van Praet JT, Vandecasteele S, De Roo A, De Vriese AS, Reynders M. (2021). Humoral and Cellular 534 Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing 535 Home Residents. Clin Infect Dis 73:2145-2147. doi: 10.1093/cid/ciab300 536 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas 537 SL, Bhorat QE, et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 538 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South 539 Africa, and the UK. Lancet 397:99-111. doi: 10.1016/S0140-6736(20)32661-1 540 Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan 541 MJ, Bailey R, et al. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine 542 Candidates. N Engl J Med 383:2439-2450. doi: 10.1056/NEJMoa2027906 543 Zeng C, Evans JP, Reisinger S, Woyach J, Liscynesky C, Boghdadly ZE, Rubinstein MP, Chakravarthy K, 544 Saif L, Oltz EM, et al. (2021). Impaired neutralizing antibody response to COVID-19 mRNA 545 vaccines in cancer patients. Cell Biosci 11:197. doi: 10.1186/s13578-021-00713-2 546 547

548 Figures Legends

549

550 Figure 1. Experimental design.

551 IgG antibody response, the CD4 and CD8 T cell activation (Ag1 and Ag2) and the neutralizing antibody 552 response to SARS-CoV-2 spike protein developed after mRNA SARS-CoV-2 vaccination (Spikevax or 553 mRNA-1273, Moderna - Comirnaty or BNT162b2, Pfizer-BioNTech) were analyzed as a part of two 554 observational studies approved by the Ethical Committee of Istituto Clinico Humanitas, in compliance with 555 the Declaration of Helsinki principles. The studies were conducted at Istituto Clinico Humanitas and 556 comprises a longitudinal sample collection, including healthcare workers (n=160) and cancer patients (n=30)557 and a cross-sectional sample collection, including elderly subjects (n=37), patients with rheumatic diseases 558 (n=48) and patients in hemodialysis (n=53). Immunocompromised patients received a third dose (booster) \pm 559 5 months after the second dose. Analyzed time points were: the day of the first dose (T0), 21-28 days after 560 the first dose (T1), 10-26 days after the second dose (T2), 2-4 months after the second dose (T3) and 2 weeks 561 after the third dose (T4).

562

Figure 2. The immune response is compromised in a substantial proportion of naïve patients in hemodialysis and in some naïve rheumatologic patients but can be boosted by a third vaccine dose.

565 IgG antibody response (A), its neutralizing activity (B) and anti-spike T cell response activation, by using 566 specific CD4 (Ag1, C) and CD4 plus CD8 (Ag2, D) T cell epitopes of the spike protein were measured in 567 serum and plasma of vaccinated naïve health care workers (HCW, n=104), elderly people \geq 75 yo (n=35), 568 cancer patients (n=9), patients with rheumatic diseases (n=47) or patients in hemodialysis (n=48) at 2-4 569 months after second dose (black, T3) and in serum and plasma of cancer patients (n=7), patients with 570 rheumatic diseases (n=30) or patients in hemodialysis (n=43) 2 weeks after the booster dose (red, T4). As a 571 control, we indicated values of IgGs, their neutralizing activity and anti-spike T cell response activation of 572 vaccinated naïve health care workers (HCW, n=119) at 10 days after the second dose (T2). The box plots 573 show the interquartile range, the horizontal lines show the median values, and the whiskers indicate the 574 minimum-to-maximum range. Each dot corresponds to an individual subject. P values were determined 575 using 2-tailed Kruskal-Wallis test with Dunn's multiple comparisons post test. P values refer to HCW T3 when there are no connecting lines. Positivity was based on: anti-spike $IgG \ge 33.8$ BAU/mL (LIAISON SARS-CoV-2 TrimericS IgG); neutralization (Neu) $\ge 30\%$ (cPass SARS-CoV-2 Neutralization Antibody Detection Kit), and T cell response $\ge 0.25 \Box IU/mL$ for either Ag1 or Ag2 (QuantiFERON SARS-CoV-2 assay).

580

581 Figure 3. The immune response depends on the type of treatment or immune status of the patients.

582 IgG antibody response (A), its neutralizing activity (B) and anti-spike T cell response activation, by using 583 specific CD4 (Ag1, C) and CD4 plus CD8 (Ag2, D) T cell epitopes of the spike protein were measured in 584 serum and plasma of vaccinated naïve patients with cancer (n=9), rheumatic diseases (n=47) or patients in 585 hemodialysis (n=48) at 2-4 months after second dose (T3) and 2 weeks after the booster dose (T4). Cancer 586 and rheumatic disease patients were classified according to the type of treatment: no active treatment or low 587 (category 0), medium (category 1) or high (category 2) interference with the immune system, whereas 588 patients in hemodialysis were classified with an immunoscore related to the disease for which the patients 589 are in dialysis and their comorbidities: low (category 0), medium (category 1) or high (category 2) immune 590 compromised. The distribution of patients in each category and the type of treatment are indicated in the 591 legend. Samples \geq 33.8 BAU/mL (IgG plasma levels) or \geq 30% signal inhibition (neutralization) and T cell 592 response $\geq 0.25 \Box IU/mL$ for either Ag1 or Ag2 were considered positive (dotted black lines). The box plots 593 show the interquartile range, the horizontal lines show the median values, and the whiskers indicate the 594 minimum-to-maximum range. Each dot corresponds to an individual subject. P values were determined 595 using 2-tailed Kruskal-Wallis test with Dunn's multiple comparisons post test. P values are reported.

596

Figure 4. Correlation between antibody levels and neutralization potential. Correlation between IgG values in serum (x variable) and the % of neutralization (y variable) was performed in each category of immunocompromised patients at T3 (0, n=23; 1, n=43; 2, n=38) (A) and at T4 (0, n=18; 1, n=30; 2, n=32) (B). A non-parametric Spearman's rank correlation test was performed. Samples \geq 33.8 BAU/mL (IgG plasma levels) or \geq 30% signal inhibition (neutralization, dotted black line) were considered positive. Log scale on x axis.

604 **Table 1. Cohort design and summary statistics.** Demographic and clinical information, including age, sex,

605 SARS-CoV-2 infection and vaccine type.

606

Table 2. Immunocompromised patients and treatments. Clinical information and treatments of patients with cancer (hematologic or solid cancer), rheumatic disease or undergoing hemodialysis. Classification in categories (0, 1, 2) is reported. Cancer and rheumatic disease patients were classified according to the type of treatment at the time of vaccination: no active treatment or low (0), medium (1) or high (2) interference with the immune system. Patients in hemodialysis were classified with an immunoscore related to the disease for which the patients are in dialysis and their comorbidities: low (0), medium (1) or high (2) immune compromised.

014





в

D











Table 1

	HCW	Elderly≥75	Cancer patients	Rheumatic disease patients	Dialysis patients
Subjects (n)	160	37	30	48	53
Sex					
Female	108 (67.5%)	20 (54.1%)	14 (46.7%)	29 (60.4%)	19 (35.8%)
Male	52 (32.5%)	17 (45.9%)	16 (53.3%)	19 (39.6%)	34 (64.2%)
Age					
Mean (Min - Max)	30.23 (19-77)	79.03 (75-87)	54.9 (35-79)	54.92 (25-78)	73.28 (50-93)
SARS-CoV-2 naturally infected					
No	124 (77.5%)	35 (94.6%)	12 (40%)	47 (97.9%)	48 (90.6%)
Yes	36 (22.5)	2 (5.4%)	18 (60%)	1 (2.1%)	5 (9.4%)
Vaccine Type					
Comirnaty Pfizer	160 (100%)	37 (100%)	30 (100%)	0 (0%)	53 (100%)
Spikevax Moderna	0 (0%)	0 (0%)	0 (0%)	48 (100%)	0 (0%)

Table 2

	CATEGORY	0		1	2
	Subjects (n)	No active	Low	Medium	High
Hematologic cancer patients	13	treatment 2	2	1	8
SARS-CoV-2 naturally infected	15	2	-	1	0
No	8	0	0	1	7
Ves	5	2	2	0	, 1
Tumor type	5	2	2	0	1
Diffuse Large B cell Lymphoma (DI BCI)	4	1	0	0	3
Hodgkin I vmnhoma (HI)	1	0	0	1	0
Follicular lymphoma (FL)	5	0	0	0	5
Multiple Myeloma (MM)	1	0	1	0	0
Chronic lymphocytic leukemia (CLL)	1	1	0	0	0
Chronic myeloid leukemia (CML)	1	0	1	0	0
Solid cancer patients	17	6	8	3	0
SARS-CoV-2 naturally infected		÷	-	-	÷
Νο	4	2	0	2	0
Yes	13	4	8	-	0
Tumor type			-	-	÷
Breast Cancer	7	2	5	0	0
Lung Cancer	2	0	2	0	0
Sarcoma	6	4	0	2	0
Pancreatic Cancer	1	0	1	0	0
Testicular cancer	1	1	0	0	0
Rheumatic disease patients	48	5	4	26	13
SARS-CoV-2 naturally infected					
No	47	5	3	26	13
Yes	1	0	1	0	0
Diagnosis					
Autoimmune hepatitis (AIH)					
	2	2	0	0	0
Psoriatic arthritis /Spondyloarthritis/Ankylosing spondylitis (PA/SpA/AS)	18	0	0	17	1
Rheumatoid arthritis (RA)	12	1	0	8	3
Primary biliary cholangitis (PBC)					
	5	1	4	0	0
Sclerosing cholangitis (SC)	1	0	0	1	0
Dermatomyositis (DM)					
	2	0	0	0	2
Systemic lupus erythematosus (SLE)					
	1	0	0	0	1
Primary Sjögren's syndrome (pSS)					
	1	0	0	0	1
Systemic sclerosis (SSc)					
	6	1	0	0	5
Dialysis patients	53	0	15	16	22
SARS-CoV-2 naturally infected					
No	48	0	12	16	20
Yes	5	0	3	0	2
Acute kidney injury (AKI) causes					
ANCA-associated vasculitis	1	0	0	0	1

Chronic Glomerulonephritis (CGN)	6	0	1	2	3	
Glomerulopathy after liver transplantation	1	0	0	0	1	
Nephrolithiasis	1	0	1	0	0	
Nephropathy	5	0	0	3	2	
Nephrosclerosis	33	0	9	11	13	
Non-Hodgkin lymphoma (NHL)	1	0	0	0	1	
Polycystic kidney disease (PKD)	5	0	4	0	1	